Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

AL-2512 as a potentially safer ocular antiinflammatory agent

Oct. 21, 2003

Visudyne approved in Japan for wet AMD

Oct. 20, 2003

Characterization of SU-10944, an orally active small-molecule inhibitor of VEGFR-2

Oct. 14, 2003

FDA accepts Vitrase NDA for filing

Oct. 10, 2003

Novartis presents new IOP-lowering agents in recent patent

Oct. 10, 2003

Improved vision observed in phase I/II trial of squalamine in wet AMD

Oct. 9, 2003

Integrin antagonists useful for angiogenesis-related ocular diseases

Sep. 30, 2003

FDA accepts for filing diquafosol NDA for dry eye

Sep. 15, 2003

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Sep. 12, 2003

Good efficacy and safety profile described for ranibizumab in AMD

Sep. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...